Depression News and Research

Latest Depression News and Research

L-methylfolate in combination with antidepressant drug helps major depressive disorder patients

Data published in the January issue of Innovations in Clinical Neuroscience, www.psychiatrymmc.com, suggest when L-methylfolate, a medical food available commercially as Deplin®, and by prescription, is used for dietary management of depression in combination with an antidepressant drug at the start of depression therapy, it results in significantly more patients experiencing major improvement and more rapid improvement than antidepressant monotherapy alone.

10 Feb 2011

FDA grants Neuralstem orphan drug designation for treatment of ALS with spinal cord stem cells

Neuralstem, Inc. announced that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted it orphan drug designation for the treatment of Amyotrophic Lateral Sclerosis (ALS) with its human spinal cord derived neural stem cells (NSI-566RSC), currently in a Phase I safety study to evaluate the safety of the product and the surgical route of administration in a wide range of ALS patients.

10 Feb 2011

New study: Testosterone administration leads to significant reduction in mind reading

A new study from Utrecht and Cambridge Universities has for the first time found that an administration of testosterone under the tongue in volunteers negatively affects a person's ability to 'mind read', an indication of empathy. The findings are published this week in the journal Proceedings of the National Academy of Sciences.

9 Feb 2011

Evotec signs definitive agreement to acquire all shares in Kinaxo

Evotec AG today announced the signing of a definitive agreement to acquire all shares in Kinaxo Biotechnologies GmbH, a Munich-based drug discovery alliance company supporting the development of targeted drugs.

9 Feb 2011

Repligen third quarter total revenue increases 26% to $7,068,000

Repligen Corporation today reported results for the third quarter of fiscal year 2011, ended December 31, 2010. Total revenue for the quarter was $7,068,000 compared to total revenue of $5,617,000 for the third quarter of fiscal year 2010 ended December 31, 2009, an increase of $1,451,000 or 26%.

9 Feb 2011

CeNeRx announces FDA approval of CXB909 IND for neuroprotection and neurodegenerative disorders

CeNeRx BioPharma, Inc., a clinical-stage company developing and commercializing innovative treatments for diseases of the central nervous system (CNS), today announced FDA approval of its IND and reported the first clinical results in humans for CXB909, a novel agent that has demonstrated utility in preclinical models of neuroprotection and neurodegenerative disorders.

9 Feb 2011

AcademyHealth recognizes military health research study with 2011 HSR Impact Award

AcademyHealth today recognized research that improves access to behavioral health care for returning U.S. service members with the 2011 Health Services Research Impact Award.

9 Feb 2011

Study: Parkinson’s disease undermines language processing ability in Dutch native speaker patients

It is becoming more generally known that Parkinson's disease not only influences a patient's motor functions. Patients often also suffer from depression, fear and incontinence, for example. However, the disease also undermines the language processing ability. University of Groningen researcher Katrien Colman has found clear indications of this in Dutch native speaker patients.

9 Feb 2011

New study finds income-related inequalities impact mental health

Due to the recent economic crisis, an increase of health inequalities between socio-economic groups has been noticed in both developed and developing countries.

9 Feb 2011

Urocortin system plays central role in regulating stress responses

Post-traumatic stress disorder can affect soldiers after combat or ordinary people who have undergone harrowing experiences. Of course, feelings of anxiety are normal and even desirable - they are part of what helps us survive in a world of real threats. But no less crucial is the return to normal - the slowing of the heartbeat and relaxation of tension - after the threat has passed.

9 Feb 2011

USPTO issues patent for Metabolon's UHPLC/MSn-based analytical platform

Metabolon, the leader in metabolomics, biomarker discovery and analysis, announced today the grant of US Patent No. 7,884,318 entitled "Systems, Methods, and Computer-Readable Medium for Determining Composition of Chemical Constituents in a Complex Mixture".

8 Feb 2011

ADHD kids often suffer from other mental ailments: Study

As many as two thirds of American children suffering from attention-deficit/hyperactivity disorder, ADHD, also suffer other mental health and developmental conditions, such as learning disabilities and anxiety says a new study.

8 Feb 2011

TREK1 activity offers a key target for fluoxetine and other antidepressant drugs

Using a unique and relatively simple cell-based fluorescent assay they developed, scientists with the U.S. Department of Energy's Lawrence Berkeley National Laboratory and the University of California, Berkeley have identified a means by which fluoxetine, the active ingredient in Prozac, suppresses the activity of the TREK1 potassium channel.

8 Feb 2011

Study identifies genetic variation linked with increased risk of major depression

Numerous studies have shown that the brain molecule neuropeptide Y (NPY) helps to restore calm after stressful events. A team of University of Michigan-led researchers has now found that people whose genes predispose them to produce lower levels of NPY are more responsive to negative stimuli in key brain circuits related to emotion - and are therefore less resilient in the face of stress and may be at higher risk for developing a major depressive disorder.

8 Feb 2011

NIMH awards two BUSM members with BRAINS grant for innovative research on mental disorders

Two Boston University School of Medicine faculty members, Pietro Cottone, PhD, an assistant professor of pharmacology and psychiatry and Michael Silverstein, MD, an associate professor of pediatrics, were each awarded the prestigious National Institute of Mental Health Biobehavioral Research Awards for Innovative New Scientisits grant with ten other investigators from around the country.

7 Feb 2011

State Roundup: Setting up health insurance exchanges; Community-based clinics cuts; Autism legislation; End-of-life care

The board of the Health Benefit Exchange is going to be small and mighty. ... This exchange will concentrate the health insurance buying power of millions of Californians, and will be the central force in implementing national health care reform in California (Gorn, 2/4).

7 Feb 2011

AstraZeneca, Targacept commence TC-5214 Phase 2b clinical trial for major depressive disorder

AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.

7 Feb 2011

WINCS device can detect and measure serotonin levels in brain: Mayo Clinic

Mayo Clinic researchers have concluded that, through deep brain stimulation, a Wireless Instantaneous Neurotransmitter Concentration System can detect and measure serotonin levels in the brain. The findings suggest that in the future such measurements of serotonin may help establish a therapeutic mechanism of deep brain stimulation for psychiatric disease.

5 Feb 2011

Amgen, Pfizer present Enbrel new trial results against psoriasis at 69th AAD meeting in New Orleans, LA

Amgen and Pfizer Inc. today announced results from a new trial that demonstrated Enbrel significantly improved scalp involvement in adult patients with moderate to severe plaque psoriasis, compared with placebo. The data will be presented today at the 69th Annual American Academy of Dermatology meeting in New Orleans, La.

5 Feb 2011

U-M Medical School earns $368.7 million in NIH research funding during federal fiscal year 2010

University of Michigan Medical School physicians and scientists earned more than $368.7 million in National Institutes of Health research funding in federal fiscal year 2010, according to NIH data. In all, the School's faculty brought in $481.8 million in research funding from all sources in U-M fiscal year 2010.

5 Feb 2011

Depression News and Research

Latest Depression News and Research

L-methylfolate in combination with antidepressant drug helps major depressive disorder patients

FDA grants Neuralstem orphan drug designation for treatment of ALS with spinal cord stem cells

New study: Testosterone administration leads to significant reduction in mind reading

Evotec signs definitive agreement to acquire all shares in Kinaxo

Repligen third quarter total revenue increases 26% to $7,068,000

CeNeRx announces FDA approval of CXB909 IND for neuroprotection and neurodegenerative disorders

AcademyHealth recognizes military health research study with 2011 HSR Impact Award

Study: Parkinson’s disease undermines language processing ability in Dutch native speaker patients

New study finds income-related inequalities impact mental health

Urocortin system plays central role in regulating stress responses

USPTO issues patent for Metabolon's UHPLC/MSn-based analytical platform

ADHD kids often suffer from other mental ailments: Study

TREK1 activity offers a key target for fluoxetine and other antidepressant drugs

Study identifies genetic variation linked with increased risk of major depression

NIMH awards two BUSM members with BRAINS grant for innovative research on mental disorders

State Roundup: Setting up health insurance exchanges; Community-based clinics cuts; Autism legislation; End-of-life care

AstraZeneca, Targacept commence TC-5214 Phase 2b clinical trial for major depressive disorder

WINCS device can detect and measure serotonin levels in brain: Mayo Clinic

Amgen, Pfizer present Enbrel new trial results against psoriasis at 69th AAD meeting in New Orleans, LA

U-M Medical School earns $368.7 million in NIH research funding during federal fiscal year 2010

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Depression News and Research

Latest Depression News and Research

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Newsletters you may be interested in